uBriGene at JPM 2026 | Cell & Gene Therapy Innovation

Accelerating innovation at the intersection of science, strategy, and healthcare investment, uBriGene Biosciences will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California.

As the premier global healthcare investment conference, JPM 2026 brings together biotech innovators, fast-growing life sciences companies, global healthcare leaders, and the investment community to shape the future of medicine. This objective closely aligns with uBriGene’s mission to advance cell and gene therapy (CGT) and advanced therapy medicinal products (ATMPs) through scalable, high-quality development, GMP manufacturing, and analytical solutions.

uBriGene Biosciences is a cell and gene therapy–focused CRDMO, delivering end-to-end ATMP services from early-stage research and IND-enabling development to GMP manufacturing, quality control, and regulatory-ready testing. Leveraging robust, productivity-optimized CDMO platforms, uBriGene specializes in plasmids, RNA-LNPs, sgRNA, viral vectors, and cell therapy products.

Complemented by advanced analytical development and GMP testing services, uBriGene partners with biotech and biopharma innovators worldwide to streamline technical R&D and IND timelines, ensure regulatory compliance, and accelerate the translation of breakthrough science into clinical and commercial success.

uBriGene’s participation reflects our commitment to strategic collaboration, knowledge exchange, and innovation leadership in cell and gene therapy manufacturing. Through engagement at this influential forum, we aim to strengthen partnerships, share insights on scalable CGT manufacturing and quality strategies, and advance our mission to deliver high-quality, patient-ready therapies.

We look forward to connecting with innovators, partners, and investors at JPM 2026 in San Francisco to explore collaborations that accelerate the future of cell and gene therapies.